LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 23

Search options

  1. Article: Effect of 24-hour blood pressure and heart rate on the prognosis of patients with reduced and midrange LVEF.

    Mareev, V Yu / Kapanadze, L G / Kheimets, G I / Mareev, Yu V

    Kardiologiia

    2021  Volume 61, Issue 7, Page(s) 4–13

    Abstract: Aim    Optimal combination therapy for chronic heart failure (CHF) currently implies the mandatory use of at least four classes of drugs: renin-angiotensin-aldosterone (RAAS) system inhibitors or angiotensin receptor blocker neprilysin inhibitors (ARNI); ...

    Abstract Aim    Optimal combination therapy for chronic heart failure (CHF) currently implies the mandatory use of at least four classes of drugs: renin-angiotensin-aldosterone (RAAS) system inhibitors or angiotensin receptor blocker neprilysin inhibitors (ARNI); beta-adrenoblockers (BAB); mineralocorticoid receptor antagonists; and sodium-glucose cotransporter 2 inhibitors. Furthermore, many of these drugs are able to decrease blood pressure even to hypotension and alleviate tachycardia. This study focused on the relationship of 24-h blood pressure (BP) and heart rate (HR) with the prognosis for CHF patients with sinus rhythm and left ventricular ejection fraction (LV EF) <50 % as well as on suggesting possible variants of safe therapy for CHF depending on the combination of studied factors.Material and methods    Effects of clinical data, echocardiographic parameters, 24-h BP, and heart rhythm (data from 24-h BP and ECG monitors) on the prognosis of 155 patients with clinically pronounced CHF, LV EF <50 %, and sinus rhythm who were followed up for 5 years after discharge from the hospital.Results    The one-factor analysis showed that the prognosis of CHF patients was statistically significantly influenced by the more severe functional class (FC) III CHF compared to FC II, reduced LV EF (<35 %), a lower 24-h systolic BP (SBP) (<103 mm Hg), the absence of hypotensive episodes in daytime, a low variability of nighttime BP (<7.5 mm Hg), a higher 24-h HR (>71 bpm vs. <60 bpm), the absence of therapy with RAAS inhibitors + BAB, and a lower body weight index. The multi-factor analysis showed that more severe CHF FC, lower LV EF, and the absence of RAAS inhibitors + BAB therapy retained the influence on the prognosis. After eliminating the influencing factor of drug therapy, also a low SBP variability significantly influenced the prognosis. An additional analysis determined the following four groups of CHF patients with reduced heart systolic function according to mean 24-h HR and SBP: the largest group (38.1 % of all patients) with controlled HR (≤69 bpm), preserved SBP (>103 mm Hg), and the lowest death rate of 15.3 %; the group with increased HR (>69 bpm) but preserved SBP (30.3 % of all patients) where the death rate was 44.7 %, which was significantly higher than in the first group; the group with normal HR (≤69 bpm) but reduced SBP (≤103 mm Hg) (16.1 % of patients) where the death rate was 40 %, which was comparable with the second group and significantly worse than in the first group; and the group with both increased HR (>69 bpm) and reduced SBP (≤103 mm Hg) (15.5 % of patients), which resulted in the maximal risk of death (70.8 % of patients with CHF and LV EF <50 %), which was significantly higher than in the three other groups.Conclusion    Low SBP (including 24-h SBP with reduced variability in day- and nighttime) in combination with high HR (including by data of Holter monitoring), low LV EF, more severe clinical course of CHF, and the absence of an adequate treatment with neurohormonal modulators (RAAS inhibitors and BAB) significantly increased the risk of death. Isolating four types of FC II-III CHF with sinus rhythm and EF <50% based on the combination of HR and BP identifies patients with an unfavorable prognosis, which will help developing differentiated therapeutic approaches taking into account clinical features.
    MeSH term(s) Blood Pressure ; Heart Failure/drug therapy ; Heart Rate ; Humans ; Prognosis ; Stroke Volume ; Ventricular Function, Left
    Language English
    Publishing date 2021-07-31
    Publishing country Russia (Federation)
    Document type Journal Article
    ZDB-ID 131029-x
    ISSN 0022-9040
    ISSN 0022-9040
    DOI 10.18087/cardio.2021.7.n1684
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: [Telomere length as a biomarker of the risk of cardiovascular complications in patients with coronary heart disease].

    Doroshchuk, N A / Lankin, V Z / Tikhaze, A K / Kheimets, G I / Doroshсhuk, A D / Smirnova, M D / Chazova, I E

    Terapevticheskii arkhiv

    2021  Volume 93, Issue 1, Page(s) 20–24

    Abstract: Aim: To study the effect of oxidative stress and telomere length in the chromosomes of blood leukocytes in patients with coronary heart disease (CHD) on the development of cardiovascular complications.: Materials and methods: In 119 patients with CHD, ...

    Abstract Aim: To study the effect of oxidative stress and telomere length in the chromosomes of blood leukocytes in patients with coronary heart disease (CHD) on the development of cardiovascular complications.
    Materials and methods: In 119 patients with CHD, the level of oxidatively modified low-density lipoproteins (ox-LDL) in blood plasma and the length of telomeres in nuclear blood cells were determined during the examination. After 5 years, a telephone survey of patients (or their relatives) was conducted to obtain data on the presence of cardiovascular complications. Telomere length was determined using quantitative real-time PCR, and the level of ox-LDL was determined by immunochemical method.
    Results: It was found that reducing the length of telomeres in patients with CHD increases the risk of subsequent development of cardiovascular complications. A strong negative correlation was found between the level of ox-LDL and telomere length in the group of examined CHD patients who had cardiovascular complications after 5 years.
    Conclusion: CHD patients with short telomere length and high levels of ox-LDL have an increased risk of cardiovascular complications during 5 years.
    MeSH term(s) Biomarkers ; Coronary Disease/diagnosis ; Coronary Disease/epidemiology ; Coronary Disease/genetics ; Humans ; Leukocytes ; Lipoproteins, LDL ; Telomere/genetics
    Chemical Substances Biomarkers ; Lipoproteins, LDL
    Language Russian
    Publishing date 2021-01-10
    Publishing country Russia (Federation)
    Document type Journal Article
    ZDB-ID 40718-5
    ISSN 2309-5342 ; 0040-3660
    ISSN (online) 2309-5342
    ISSN 0040-3660
    DOI 10.26442/00403660.2021.01.200588
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: [Adhesion Molecules and Subpopulation of Mononuclear Cells in Pulmonary Arteries].

    Chumachenko, P V / Leusova, Y Yu / Kheimets, G I / Chasova, E I

    Kardiologiia

    2017  Volume 56, Issue 3, Page(s) 35–39

    Abstract: Atherosclerosis is associated with increased expression of adhesion molecules by vascular endothelium.: Aim: to study endothelial expression of platelet endothelial cellular adhesion molecules (PECAM) (CD31), intercellular adhesion molecules (ICAM-1), ...

    Abstract Atherosclerosis is associated with increased expression of adhesion molecules by vascular endothelium.
    Aim: to study endothelial expression of platelet endothelial cellular adhesion molecules (PECAM) (CD31), intercellular adhesion molecules (ICAM-1), vascular cell adhesion molecules (VCAM-1F) as well as T-cells and monocytes adhered to endothelium.
    Methods: Research materials were en face specimens.
    MeSH term(s) Cell Adhesion Molecules ; Humans ; Intercellular Adhesion Molecule-1 ; Leukocytes/metabolism ; Pulmonary Artery/cytology ; Pulmonary Artery/metabolism ; Vascular Cell Adhesion Molecule-1
    Chemical Substances Cell Adhesion Molecules ; Vascular Cell Adhesion Molecule-1 ; Intercellular Adhesion Molecule-1 (126547-89-5)
    Language Russian
    Publishing date 2017-03-13
    Publishing country Russia (Federation)
    Document type Journal Article
    ZDB-ID 131029-x
    ISSN 0022-9040
    ISSN 0022-9040
    DOI 10.18565/cardio.2016.3.35-39
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article: Vospalitel'nye infil'traty, vasa vasorum i NO-sintaza éndoteliia v stenke anevrizmy grudnogo otdela aorty.

    Chumachenko, P V / Afanasyev, M A / Ivanova, A G / Drobkova, I P / Kheimets, G I / Postnov, A Yu

    Arkhiv patologii

    2019  Volume 81, Issue 5, Page(s) 45–52

    Abstract: Objective: To elucidate whether there is a relationship between inflammation of the wall of aortic aneurysm and the number of vasa vasorum in it.: Material and methods: The investigation material was aortic aneurysm wall segments obtained during ... ...

    Title translation Inflammatory infiltrates, vasa vasorum, and endothelial NO synthase in the wall of thoracic aortic aneurysm.
    Abstract Objective: To elucidate whether there is a relationship between inflammation of the wall of aortic aneurysm and the number of vasa vasorum in it.
    Material and methods: The investigation material was aortic aneurysm wall segments obtained during surgery. Among the patients, there were 20 men and 5 women. The patients' age ranged from 33 to 69 years. The investigation used monoclonal antibodies to macrophages (CD68), T cells (CD3, CD4, and CD8) and antibodies to von Willebrand factor, endothelial NO synthase, and alpha smooth muscle actin. A morphometric study was conducted.
    Results: Calculation of the number of vasa vasorum (including newly formed vessels) in the adventitia of aortic aneurysm revealed that there was a statistically significant difference between the number of vasa vasorum in patients with an active inflammatory response (Group 1) versus Group 2 patients with a moderate inflammatory process in the aneurysm wall (p≤0.05) and a statistically significant difference between Groups 1 and 3 (without inflammatory infiltrates) (p≤0.05). Endothelial vasa vasorum heterogeneity was found in case of an immune response to NO synthase. At the same time individual vasa vasorium did not contain NO synthase, this enzyme was identified in the endothelium in a number of nearby vessels.
    Conclusion: The increase in the number of vasa vasorum in the aneurysm wall in patients with abundant inflammatory infiltrates is due to the fact that some of the inflammatory cytokines of T-cells and macrophages also contribute to angiogenesis.
    MeSH term(s) Adult ; Adventitia/blood supply ; Aged ; Aortic Aneurysm, Thoracic/pathology ; Female ; Humans ; Inflammation/pathology ; Male ; Middle Aged ; Neovascularization, Pathologic ; Nitric Oxide Synthase Type III/metabolism ; Vasa Vasorum/pathology
    Chemical Substances NOS3 protein, human (EC 1.14.13.39) ; Nitric Oxide Synthase Type III (EC 1.14.13.39)
    Language Russian
    Publishing date 2019-10-18
    Publishing country Russia (Federation)
    Document type Journal Article
    ZDB-ID 127285-8
    ISSN 0004-1955
    ISSN 0004-1955
    DOI 10.17116/patol20198105145
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article: [Results of using the dosing Valsalva-Weber test to determine autonomic disorders in patients with vasovagal syncope].

    Ziuzina, N E / Pevzner, A V / Kheĭmets, G I / Rogoza, A N / Ermishkin, V V / Goncharov, M D

    Terapevticheskii arkhiv

    2014  Volume 86, Issue 9, Page(s) 97–101

    Abstract: Aim: To estimate the value of the dosing Valsalva-Weber test (VWT) in the diagnosis of autonomic disorders in patients with vasovagal syncope (VVS).: Subjects and methods: The dosing VWT using a specialized Task Force Monitor unit ("CNSystem", ... ...

    Abstract Aim: To estimate the value of the dosing Valsalva-Weber test (VWT) in the diagnosis of autonomic disorders in patients with vasovagal syncope (VVS).
    Subjects and methods: The dosing VWT using a specialized Task Force Monitor unit ("CNSystem", Austria) with synchronous noninvasive ECG and blood pressure (BP) monitoring was carried out in 30 patients (mean age 32 ± 14 years) with VVS and 12 healthy individuals (31 ± 7 years). The analysis of the test results encompassed the visual assessment of BP change curves and heart rate in different test phases and the calculation of pressure indices, Valsalva coefficient, arterial baroreflex sensitivity, and other parameters (a total of 26).
    Results: The abnormally changed form of the mean BP curve, which was characterized by that BP by the end of Phase II test failed to achieve the baseline level, was recorded in 10 (33%) patients with VVS and in none of the healthy individuals (p = 0.04). An individual analysis of the gender- and age-adjusted Valsalva coefficient revealed its reduction in 9 (30%) patients while this indicator was within the normal range in all the healthy individuals (p = 0.04).
    Conclusion: During the dosing VWT, the signs of sympathetic insufficiency (impaired adrenergic regulation of BP) are found in 33% of the patients with VVS and those of parasympathetic insufficiency (impaired vagus regulation of cardiochronotropic function) are in 30%.
    MeSH term(s) Adult ; Autonomic Nervous System/physiopathology ; Autonomic Nervous System Diseases/complications ; Autonomic Nervous System Diseases/diagnosis ; Autonomic Nervous System Diseases/physiopathology ; Baroreflex/physiology ; Blood Pressure/physiology ; Female ; Heart Rate/physiology ; Humans ; Male ; Middle Aged ; Physical Examination/methods ; Syncope, Vasovagal/etiology ; Syncope, Vasovagal/physiopathology ; Valsalva Maneuver
    Language Russian
    Publishing date 2014
    Publishing country Russia (Federation)
    Document type English Abstract ; Journal Article
    ZDB-ID 40718-5
    ISSN 2309-5342 ; 0040-3660
    ISSN (online) 2309-5342
    ISSN 0040-3660
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: [Influence of intensive hypolipidemic therapy on blood concentration of lipoprotein-associated phospholipase A2 in patients with ischemic heart disease].

    Miklishanskaia, S V / Vlasik, T N / Kheĭmets, G I / Kaznacheeva, E I / Liakishev, A A / Kukharchuk, V V

    Kardiologiia

    2013  Volume 53, Issue 9, Page(s) 4–11

    Abstract: Aim: To assess the impact of combined treatment with simvastatin and ezetimibe or treatment with simvastatin only on lipoprotein-associated phospholipase A2 in patients with ischemic heart disease.: Methods: One hundred patients with angiographically ...

    Abstract Aim: To assess the impact of combined treatment with simvastatin and ezetimibe or treatment with simvastatin only on lipoprotein-associated phospholipase A2 in patients with ischemic heart disease.
    Methods: One hundred patients with angiographically documented coronary atherosclerosis took part in the investigation. Lp-PLA2 mass and cholesterol fractions were determined at baseline and after 6 months of treatment. Lp-PLA2 mass was determined by enzyme immunoassay method, using two highly specific monoclonal antibodies.
    Results: Combined treatment with ezetimibe and simvastatin led to significantly greater declines in Lp-PLA2 and cholesterol fractions compared with treatment only with simvastatin: Lp-PLA2 decreased by 46 vs 38%, total cholesterol by 35 vs 28%, LDL cholesterol by 50 vs 40%, respectively (p<0.05). Combination therapy with ezetimibe and simvastatin 20 and 40mg/day proved to be as effective as monotherapy with simvastatin 80 mg/day on the effect on Lp-PLA2 mass and cholesterol fractions (p<0.05). Lp-PLA2 correlated positively with total cholesterol (r=0.28) and LDL-C (r=0.33).
    Conclusions: Combined treatment led to greater reduction of total cholesterol and LDL-C, as well as significantly reduced level of Lp-PLA2 mass. The latter can be considered as target for suppression of inflammation and achievement of stabilization of atherosclerotic plaque.
    MeSH term(s) 1-Alkyl-2-acetylglycerophosphocholine Esterase/blood ; Adult ; Aged ; Anticholesteremic Agents/administration & dosage ; Azetidines/administration & dosage ; Cholesterol/blood ; Coronary Angiography ; Coronary Artery Disease/blood ; Coronary Artery Disease/diagnosis ; Coronary Artery Disease/drug therapy ; Drug Monitoring ; Drug Therapy, Combination ; Ezetimibe ; Female ; Humans ; Lipid Metabolism/drug effects ; Male ; Middle Aged ; Severity of Illness Index ; Simvastatin/administration & dosage ; Treatment Outcome
    Chemical Substances Anticholesteremic Agents ; Azetidines ; Cholesterol (97C5T2UQ7J) ; Simvastatin (AGG2FN16EV) ; 1-Alkyl-2-acetylglycerophosphocholine Esterase (EC 3.1.1.47) ; Ezetimibe (EOR26LQQ24)
    Language Russian
    Publishing date 2013
    Publishing country Russia (Federation)
    Document type English Abstract ; Journal Article ; Randomized Controlled Trial
    ZDB-ID 131029-x
    ISSN 0022-9040
    ISSN 0022-9040
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article: [Comparative efficacy and tolerance of atenolol and midodrine in patients with vasovagal syncopes].

    Kuchinskaia, E A / Pevzner, A V / Vershuta, E V / Al'bitskaia, K V / Kheĭmets, G I / Rogoza, A N / Golitsyn, S P

    Terapevticheskii arkhiv

    2006  Volume 78, Issue 4, Page(s) 64–68

    Abstract: Aim: To compare efficacy and tolerance of atenolol and midodrine in patients with vasovagal syncopes (VVS).: Material and methods: The trial included 35 patients with recurrent VVS confirmed at long passive head-up tilt table test (HTTT) or maximal ... ...

    Abstract Aim: To compare efficacy and tolerance of atenolol and midodrine in patients with vasovagal syncopes (VVS).
    Material and methods: The trial included 35 patients with recurrent VVS confirmed at long passive head-up tilt table test (HTTT) or maximal load bicycle exercise test (MET). These tests were also used for assessing efficacy of atenolol and midodrine in cases when syncopes occur in repeated tests. If recurrent induction of VVS was absent, efficacy of the drugs was assessed by long-term (up to 12 months) clinical observation. Long-term administration of atenolol and midodrine was continued in patients with effect by HTTT and/or MET. Eighteen patients were randomized to take atenolol in a daily dose up to 50 mg, seventeen--to take midodrine in a daily dose up to 15 mg.
    Results: Efficacy of atenolol by HTTT and MET was 8%, midodrine--57% (p = 0.01). All the patients benefited from the drugs in their long-term regimen. Long-term administration of atenolol induced remission of VVS in 82% cases, midodrine--in 89% (insignificant). Overall efficacy of atenolol was 44%, of midodrine--70% (insignificant). In 5 of 6 patients resistant to atenolol and midodrine monotherapy, combined use of the drugs was effective. Treatment with atenolol, midodrine and their combination prevented VVS in 89% patients. Both short- and long-term courses of atenolol and midodrine were safe in terms of side effects.
    Conclusion: Atenolol and midodrine as well as their combination were highly effective and well tolerated in the treatment of VVS patients.
    MeSH term(s) Adolescent ; Adrenergic alpha-Agonists/therapeutic use ; Adrenergic beta-Antagonists/therapeutic use ; Adult ; Aged ; Atenolol/therapeutic use ; Drug Therapy, Combination ; Exercise Test ; Female ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Midodrine/therapeutic use ; Syncope, Vasovagal/drug therapy ; Syncope, Vasovagal/physiopathology ; Tilt-Table Test ; Time Factors ; Treatment Outcome
    Chemical Substances Adrenergic alpha-Agonists ; Adrenergic beta-Antagonists ; Atenolol (50VV3VW0TI) ; Midodrine (6YE7PBM15H)
    Language Russian
    Publishing date 2006
    Publishing country Russia (Federation)
    Document type Comparative Study ; English Abstract ; Journal Article ; Randomized Controlled Trial
    ZDB-ID 40718-5
    ISSN 2309-5342 ; 0040-3660
    ISSN (online) 2309-5342
    ISSN 0040-3660
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article: Sostoianie krovotoka v patologicheski izmenennykh magistral'nykh arteriiakh golovy u bol'nykh gipertonicheskoĭ bolezn'iu.

    Denisova, G A / Oshchepkova, E V / Balakhonova, T V / Kheĭmets, G I / Arabidze, G G

    Terapevticheskii arkhiv

    2000  Volume 72, Issue 2, Page(s) 49–52

    Abstract: Aim: To assess blood flow in intracranial internal carotid and vertebral arteries in patients with essential hypertension (EH) and hemodynamically insignificant atherosclerotic lesions and deformities of major arteries of the head (MAH).: Materials ... ...

    Title translation Blood flow in affected major arteries of head in hypertensive patients.
    Abstract Aim: To assess blood flow in intracranial internal carotid and vertebral arteries in patients with essential hypertension (EH) and hemodynamically insignificant atherosclerotic lesions and deformities of major arteries of the head (MAH).
    Materials and methods: The blood flow was assessed in 55 untreated patients (mean age 53 +/- 1 years) with mild, moderate or severe hypertension. 20 healthy patients served control. Duplex scanning was performed using ACUSON unit.
    Results: Total blood flow (Q) in hypertensive subjects appeared significantly subnormal. It was less in patients with hemodynamically insignificant atherosclerotic stenosis and flexures of the carotid and vertebral arteries than in patients with affection of the carotid arteries only. Q in MAH was lower in smokers than in non-smokers.
    MeSH term(s) Adult ; Aged ; Arteriosclerosis/complications ; Arteriosclerosis/diagnostic imaging ; Arteriosclerosis/physiopathology ; Blood Flow Velocity ; Brain/blood supply ; Carotid Artery, Internal/diagnostic imaging ; Carotid Artery, Internal/physiopathology ; Female ; Humans ; Hypertension/complications ; Hypertension/diagnostic imaging ; Hypertension/physiopathology ; Male ; Middle Aged ; Severity of Illness Index ; Ultrasonography, Doppler, Duplex ; Vertebral Artery/diagnostic imaging ; Vertebral Artery/physiopathology
    Language Russian
    Publishing date 2000
    Publishing country Russia (Federation)
    Document type Comparative Study ; Journal Article
    ZDB-ID 40718-5
    ISSN 2309-5342 ; 0040-3660
    ISSN (online) 2309-5342
    ISSN 0040-3660
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article: Rezul'taty primeneniia midodrida dla lecheniia bolnykh vazovagal'nymi obmorokami.

    Kuchinskaia, E A / Pevzner, A V / Vershuta, E V / Al'bitskaia, K V / Kheĭmets, G I / Rogoza, A N / Golitsyn, S P

    Terapevticheskii arkhiv

    2004  Volume 76, Issue 8, Page(s) 38–41

    Abstract: Aim: To elicit efficacy of midodrin in patients with vasovagal syncope.: Material and methods: 50 patients with recurrent vasovagal syncope documented by head-up tilt tests or bicycle exercise stress tests participated in the study. These tests ... ...

    Title translation Results of midodrin treatment of vasovagal syncope.
    Abstract Aim: To elicit efficacy of midodrin in patients with vasovagal syncope.
    Material and methods: 50 patients with recurrent vasovagal syncope documented by head-up tilt tests or bicycle exercise stress tests participated in the study. These tests controlled the effects of midodrin if syncopes occurred again in repetition of the tests. In the other patients the effect of the drug was assessed clinically. All the patients received midodrin in daily dose up to 15 mg.
    Results: Mirodrin effectively prevented syncope in 13 (72%) patients as shown by the tilt test, in 10 (59%) patients as shown by the exercise stress tests and in 14 (93%) patients as controlled clinically. Total efficacy of midodrin was 74% (37 of 50 patients).
    Conclusion: Midodrin demonstrated high efficacy in prevention of vasovagal syncope. Side effects were not serious therefore the drug is well tolerated.
    MeSH term(s) Adolescent ; Adult ; Aged ; Drug Tolerance ; Female ; Humans ; Male ; Middle Aged ; Midodrine/adverse effects ; Midodrine/therapeutic use ; Syncope, Vasovagal/prevention & control
    Chemical Substances Midodrine (6YE7PBM15H)
    Language Russian
    Publishing date 2004
    Publishing country Russia (Federation)
    Document type Clinical Trial ; English Abstract ; Journal Article
    ZDB-ID 40718-5
    ISSN 2309-5342 ; 0040-3660
    ISSN (online) 2309-5342
    ISSN 0040-3660
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article: [Optimization of use of beta-adrenoblockers in the treatment of chronic heart failure in the outpatient setting].

    Zhubrina, E S / Ovchinnikov, A G / Seredenina, E M / Patrusheva, I F / Blankova, Z N / Kuz'mina, A E / Kheĭmets, G I / Ageev, F T

    Terapevticheskii arkhiv

    2009  Volume 81, Issue 11, Page(s) 35–40

    Abstract: Aim: to evaluate of the effectiveness of switching from beta-adrenoblockers (BAB) non-included into the guidelines for the management of chronic heart failure (CHF) to nebivolol and bisoprolol for outpatients.: Subjects and methods: The study ... ...

    Abstract Aim: to evaluate of the effectiveness of switching from beta-adrenoblockers (BAB) non-included into the guidelines for the management of chronic heart failure (CHF) to nebivolol and bisoprolol for outpatients.
    Subjects and methods: The study included 67 patients with stable Functional Classes (FC) II and II CHF who received the standard therapy and BAB non-included into the guidelines for the management of CHF. The patients were randomized to the groups taking bisoprolol (n = 35) or nebivolol (n = 32) in doses of 1.25 to 10 mg/day. Before and 6 months after therapy, the investigators assessed the patient's clinical status and quality of life (QL), performed a six-minute walk test and echography, and determined the blood level of the N-terminal fragment of brain natriuretic peptide prohormone (NT-proBNP).
    Results: The switching to bisoprolol and nebivolol was followed by a significant clinical improvement, a larger covered distance, and better QL. Left ventricular ejection fraction was increased along with a reduction in mean FC CHF. There were no significant changes in NT-proBNP in the total patient group, but it was significantly decreased in the subgroup of those with the baseline high level of the peptide.
    Conclusion: The switching of patients with stable CHF from therapy with BAB not included into the guidelines for the management of CHF to nebivolol or bisoprolol yields positive results and improves left ventricular systolic function (which is attended by the reduction in NT-proBNP levels) and may be recommended for treatment in the outpatient setting.
    MeSH term(s) Adrenergic beta-Antagonists/administration & dosage ; Aged ; Ambulatory Care ; Benzopyrans/administration & dosage ; Bisoprolol/administration & dosage ; Chronic Disease ; Ethanolamines/administration & dosage ; Female ; Heart Failure/drug therapy ; Heart Ventricles/drug effects ; Humans ; Male ; Middle Aged ; Nebivolol ; Treatment Outcome ; Ventricular Dysfunction, Left/drug therapy ; Ventricular Function, Left/drug effects
    Chemical Substances Adrenergic beta-Antagonists ; Benzopyrans ; Ethanolamines ; Nebivolol (030Y90569U) ; Bisoprolol (Y41JS2NL6U)
    Language Russian
    Publishing date 2009
    Publishing country Russia (Federation)
    Document type English Abstract ; Journal Article ; Randomized Controlled Trial
    ZDB-ID 40718-5
    ISSN 2309-5342 ; 0040-3660
    ISSN (online) 2309-5342
    ISSN 0040-3660
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top